The Shareholders Foundation announces that an investor, who purchased NYSEMKT:TXMD shares, filed a lawsuit against TherapeuticsMD Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.
Investors who purchased shares of TherapeuticsMD Inc (NYSEMKT:TXMD) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff claims that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: the Company’s New Drug Application (NDA) submission for TX-004HR was deficient, that the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient, and that the deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.
On April 10, 2017, TherapeuticsMD Inc announced receipt of a letter from the U.S. Food and Drug Administration (“FDA”stating that its ongoing review of the Company’s New Drug Application (NDA) for TX-004HR has discovered “deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.
Those who purchased NYSEMKT:TXMD shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com